Tag: 215798-19-9

215798-19-9, 6-Bromo-1,2,3,4-tetrahydroisoquinoline hydrochloride is a tetrahydroisoquinoline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,215798-19-9

Step B: Acryloyl chloride (1.0 g, 11 mmol, 1.2 eq.) was added to a solution of 6-bromo-I, 2,3,4-tetrahydroisoquinolinehydrochloride (2.0 g, 9 mmol, 1 eq.) and triethylamine (2.9 g, 28 mmol, 3.0 eq) in DCM (40 mL) at 0C. The mixturewas stirred at 15C for 14 hours. The reaction mixture was poured into water (30 mL) and extracted with DCM (50mL 3 2). The organic phase was dried with anhydrous Na2SO4 and concentrated in vacuum. The residue waspurified by column chromatography to give 1-(6-bromo-1,2,3,4-tetrahydroisoquinolin-yl)propyl-2-en-1-one (1.4 g, 5mmol, 56% yield) as a yellow oil. MS (ESI) m/z: 266 (M + 1).

The synthetic route of 215798-19-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; CHEN, Shuhui; DING, Charles Z.; YAN, Xiaobing; HUANG, Wei; HU, Guoping; LI, Jian; ZHANG, Xiquan; YANG, Ling; XU, Hongjiang; (121 pag.)EP3248968; (2017); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.215798-19-9,6-Bromo-1,2,3,4-tetrahydroisoquinoline hydrochloride,as a common compound, the synthetic route is as follows.,215798-19-9

To a stirred solution of 6-bromo-l,2,3,4-tetrahydro-isoquinoline hydrochloride (3.09 g, 12.4 mmol) in acetonitrile (50.0 ml) is added 2-chloro-(4-cyclobutyl-piperazine)-acetamide (2.69 mg, 12.4 mmol, 1.0 eq.), K2CO3 (5.14 g, 37.3 mmol, 3.0 eq.), and NaI (400 mg). The resulting mixture is stirred at it overnight. Water (40.0 ml) is added to quench the reaction, and then the acetonitrile is evaporated. The residue is extracted with DCM (40 ml x 3). The combined organic phase is dried over sodium sulfate, and the solvent is removed under reduced pressure to give a residue that is purified by flash silica gel chromatography (EtOAc / 4% TEA) to give the title compound. MS (+VE) m/z 392.2 (M+ +1).

The synthetic route of 215798-19-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; NEUROGEN CORPORATION; WO2007/106349; (2007); A2;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

The tetrahydroisoquinoline compound, cas is 215798-19-9 name is 6-Bromo-1,2,3,4-tetrahydroisoquinoline hydrochloride, mainly used in chemical industry, its synthesis route is as follows.

6-bromo- 1 ,2,3,4-tetrahydroisoquinoline hydrochloride (1. 5g, 6 mmol),and potassium carbonate (1.7g, 12 mmol) were taken in acetone (100 mL). 2,4,6- tnmethylbenzenesulfonyl chloride (1.6g, 7.2 mmol) was added to the reaction mixture andstirred at ambient temperature for 1 6h. Crude reaction mixture was concentrated under reduced pressure, extracted with saturated bicarbonate and brine, dried and concentrated. The crude mixture was purified on silica using ethyl acetate-hexane (3 0-70) to obtain the title compound (2.OOg, 85% yield). ?H NMR (400 MHz, DMSO-d6) oe ppm 2.27 – 2.29 (m, 3 H)2.54 (s, 6 H) 2.81 (t, J=6.00 Hz, 2 H) 3.39 (t, J=5.99 Hz, 2 H) 4.25 (s, 2 H) 7.09 (s, 3 H) 7.16(d, J8.31 Hz, 2 H) 7.33 – 7.36 (m, 2 H) 7.38 (m, J=2.00 Hz, 2 H). MS (m/z): 396.0, 397.0(M+H) for two bromine isomers., 215798-19-9

With the rapid development of chemical substances, we look forward to future research findings about 215798-19-9

Reference£º
Patent; SAINT LOUIS UNIVERSITY; BURRIS, Thomas; WALKER, Jonn, K.; FLAVENY, Colin; CHATTERJEE, Arindam; (117 pag.)WO2017/223514; (2017); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

The tetrahydroisoquinoline compound, cas is 215798-19-9 name is 6-Bromo-1,2,3,4-tetrahydroisoquinoline hydrochloride, mainly used in chemical industry, its synthesis route is as follows.

To a mixture of 6-bromo-l,2,3,4-tetrahydro-isoquinoline (10.60 g, 50 mmol) and t- butyl bromoacetate (9.95 g, 51 mmol, 1.02 eq.) in aceto?itrile (100 ml) are added sodium carbonate (10.6 g, 100 mmol, 2.0 eq.) and NaI ( 375 mg, 2.5 mmol, 0.05 eq.). The resulting mixture is stirred at rt for 16 hr. Water (100 ml) is added to quench the reaction, and the acetonitrile is evaporated. The residue is extracted with EtOAc (100 ml x 3), and the combined organic phase is dried over sodium sulfate and concentrated. The residue is purified by silica gel flash chromatography (EtOAc/hexane, 1 :4) to give the title compound.MS (+VE) m/z 326.10 (M++l)., 215798-19-9

With the rapid development of chemical substances, we look forward to future research findings about 215798-19-9

Reference£º
Patent; NEUROGEN CORPORATION; WO2007/106349; (2007); A2;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.215798-19-9,6-Bromo-1,2,3,4-tetrahydroisoquinoline hydrochloride,as a common compound, the synthetic route is as follows.

As an alternative procedure to that contained within Description 1, a solution of 6-bromo-1,2,3,4-tetrahydroisoquinoline hydrochloride (6.0 g, 24 mmol) and triethylamine (7.4 ml, 5.36 g, 53 mmol) in dichloromethane (100 ml) was treated with trifluoroacetic anhydride (3.7 ml, 5.54 g, 26.4 mmol) with ice cooling. Mixture was stirred at 20[deg.] C. for 1.5 h. then partitioned between saturated aqueous NaHCO3 (250 ml) and dichloromethane (3*50 ml). Combined organic extracts were dried (Na2SO4) and evaporated in vacuo to give a solid (8.3 g). A mixture of the latter with copper (I) cyanide (5.1 g, 56.6 mmol) in 1-methyl-2-pyrrolidinone (100 ml) was heated at reflux under argon for 4 h, then cooled and partitioned between water (300 ml), 0.880 aqueous ammonia (100 ml) and dichloromethane (5*200 ml). Combined organic extracts were dried (Na2SO4) and evaporated in vacuo to give an oil. The latter was dissolved in ether and treated with ethereal HCl to give the title compound (4.47 g, 85%) as a colourless solid. [0130] Mass spectrum (API<+>): Found 159 (MH<+>). C10H10N2 requires 158.

As the paragraph descriping shows that 215798-19-9 is playing an increasingly important role.

Reference£º
Patent; SmithKline Beecham, p.l.c.; US2003/191314; (2003); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.215798-19-9,6-Bromo-1,2,3,4-tetrahydroisoquinoline hydrochloride,as a common compound, the synthetic route is as follows.

Step A: Preparation of l-(6-Bromo-3,4-dihydroisoquinolin-2(li/)-yl)-2- hydroxyethanone.A 4 L jacketed reactor equipped with mechanical stirrer, thermocouple, gas inlet, heating/cooling and condenser was charged with 6-bromo-l,2,3,4-tetrahydroisoquinoline hydrochloride (150 g, 603 mmol), followed by dichloromethane (2.8 L), and the resulting slurry was mechanically stirred. Glycolic acid (55.07 g, 724 mmol) was added, followed by 1- hydroxybenzotriazole hydrate (101.66 g, 672 mmol) and N-(dimethylaminopropyl),N- ethylcarbodiimide hydrochloride (173.5 g, 905 mmol), followed by additional dichloromethane (0.2 L). With efficient stirring, 4-methylmorpholine (134.29 g, 1.327 mol) was slowly added in portions, while cooling to maintain a temperature at or below 25 0C, and then the reaction mixture was stirred overnight at ambient temperature. The reaction mixture was then treated with 1 nu HCl (2 L), resulting in formation of solids, which were removed by filtration. The aqueous layer was then removed, and the organic layer was washed with water (150 mL). The organic extract was dried over MgSO4 filtered, and the solvent was removed from the filtrate to provide a golden yellow oil (190.6 g). The oil was then suspended in 1 nu NaOH (1 L), and stirred until fine colorless solids separated out. The solids were collected by filtration and rinsed with water (2 x 200 mL). A second batch of the same scale was prepared under identical conditions, and the solids were consolidated at this stage. After filtering and rinsing with additional water (4 x 500 mL), the combined solid was dried in a vacuum oven at 45 0C for 48 h to provide the title compound (292 g). LCMS m/z = 270.1 [M+H]+; 1H NMR (400 MHz, CDCl3) delta 2.48 (bs, IH), 2.91 (m, 2H), 3.55 (t, J = 5.9 Hz, 1.2H), 3.89 (t, J= 6.1 Hz, 0.8H), 4.26 (m, 2H), 4.40 (s, 0.8H), 4.75 (s, 1.2H), 7.00 (d, J = 8.3 Hz, 0.4H), 7.07 (d, J= 8.3 Hz, 0.6H), 7.37 (m, 2H).

As the paragraph descriping shows that 215798-19-9 is playing an increasingly important role.

Reference£º
Patent; ARENA PHARMACEUTICALS, INC.; WO2009/105206; (2009); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.215798-19-9,6-Bromo-1,2,3,4-tetrahydroisoquinoline hydrochloride,as a common compound, the synthetic route is as follows.

6-bromo- 1 ,2,3,4-tetrahydroisoquinoline hydrochloride (1. 5g, 6 mmol),and potassium carbonate (1.7g, 12 mmol) were taken in acetone (100 mL). 2,4,6- tnmethylbenzenesulfonyl chloride (1.6g, 7.2 mmol) was added to the reaction mixture andstirred at ambient temperature for 1 6h. Crude reaction mixture was concentrated under reduced pressure, extracted with saturated bicarbonate and brine, dried and concentrated. The crude mixture was purified on silica using ethyl acetate-hexane (3 0-70) to obtain the title compound (2.OOg, 85% yield). ?H NMR (400 MHz, DMSO-d6) oe ppm 2.27 – 2.29 (m, 3 H)2.54 (s, 6 H) 2.81 (t, J=6.00 Hz, 2 H) 3.39 (t, J=5.99 Hz, 2 H) 4.25 (s, 2 H) 7.09 (s, 3 H) 7.16(d, J8.31 Hz, 2 H) 7.33 – 7.36 (m, 2 H) 7.38 (m, J=2.00 Hz, 2 H). MS (m/z): 396.0, 397.0(M+H) for two bromine isomers.

215798-19-9 6-Bromo-1,2,3,4-tetrahydroisoquinoline hydrochloride 22570216, atetrahydroisoquinoline compound, is more and more widely used in various.

Reference£º
Patent; SAINT LOUIS UNIVERSITY; BURRIS, Thomas; WALKER, Jonn, K.; FLAVENY, Colin; CHATTERJEE, Arindam; (117 pag.)WO2017/223514; (2017); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.215798-19-9,6-Bromo-1,2,3,4-tetrahydroisoquinoline hydrochloride,as a common compound, the synthetic route is as follows.

To a solution of 6-bromo- I ,2,3,4-tetrahydroisoquinoline hydrochloride (2.8 g, 11.3 mmol) inMeCN (50 mL) was added benzyl bromide (2.1 g, 12.4 mmol) and Cs2CO3 (11.1 g, 33.9 mmol).After addition, the resulting mixture was heated at reflux for I h. The solvent was evaporatedunder reduced pressure and the residue was dissolved in ethyl acetate (100 mL). The solutionwas then washed with brine (100 mL), dried (Na2SO4) and concentrated under reduced pressure. The crude product was purified by silica-gel chromatography (petroleum ether: ethyl acetate = 10:1) to give the title compound (2.7 g, 79% yield) as a colourless oil.

As the paragraph descriping shows that 215798-19-9 is playing an increasingly important role.

Reference£º
Patent; GENENTECH, INC.; CONSTELLATION PHARMACEUTICALS, INC.; ALBRECHT, Brian, K.; COTE, Alexandre; GEHLING, Victor; HSIAO-WEI TSUI, Vickie; KIEFER, James, Richard, Jr.; LIANG, Jun; MAGNUSON, Steven; NASVESCHUK, Christopher, G.; PASTOR, Richard; ROMERO, F. Anthony; TAYLOR, Alexander, M.; ZHANG, Birong; (287 pag.)WO2016/112284; (2016); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem